Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Hansoh Pharmaceutical Dividend Announcement
• Hansoh Pharmaceutical announced a quarterly dividend of HK$0.20 per ordinary share which will be made payable on 2024-10-30. Ex dividend date: 2024-09-20
• Hansoh Pharmaceutical annual dividend for 2024 was HK$0.34
• Hansoh Pharmaceutical annual dividend for 2023 was HK$0.19
• Hansoh Pharmaceutical's trailing twelve-month (TTM) dividend yield is 1.68%
• Hansoh Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 13.83%
Hansoh Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-20 | HK$0.20 | quarterly | 2024-10-30 |
2024-06-19 | HK$0.14 | quarterly | 2024-07-17 |
2023-09-15 | HK$0.07 | quarterly | 2023-09-28 |
2023-09-07 | HK$0.07 | quarterly | |
2023-06-05 | HK$0.05 | quarterly | 2023-07-05 |
2022-09-08 | HK$0.05 | quarterly | 2022-09-30 |
2022-06-16 | HK$0.09 | quarterly | 2022-07-15 |
2022-06-06 | HK$0.09 | quarterly | |
2021-06-10 | HK$0.08 | quarterly | 2021-07-05 |
2021-06-07 | HK$0.08 | quarterly |
Hansoh Pharmaceutical Dividend per year
Hansoh Pharmaceutical Dividend growth
Hansoh Pharmaceutical Dividend Yield
Hansoh Pharmaceutical current trailing twelve-month (TTM) dividend yield is 1.68%. Interested in purchasing Hansoh Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Hansoh Pharmaceutical Financial Ratios
Hansoh Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Hansoh Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Hansoh Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Hansoh Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Hansoh Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Hansoh Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Hansoh Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Hansoh Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Hansoh Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Hansoh Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Hansoh Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Hansoh Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.